4P-Pharma
- Company typePrivate
- Founded2014
- HeadquartersLille, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
4P-Pharma firmographics
Firmographics- Name
- 4P-Pharma
- Legal name
- 4P-Pharma
- Website
- https://4p-pharma.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
4P-Pharma industry classification
Industry- Product category
- Clinical-stage biotechnology / Pharmaceutical drug development
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where 4P-Pharma is headquartered
LocationHeadquarters
- HQ city
- Lille
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
4P-Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Therapeutic Development and Licensing: The company develops drug candidates through its SPV model and plans to commercialize through strategic alliances and licensing agreements by territory and therapeutic area
- SPV Equity Value: Creating value through subsidiary companies (4Moving Biotech, 4Living Biotech, Dev4All) with independent funding rounds and growth trajectories
Go-to-market motion3 records
Distribution channels3 records
Marketing channels4 records
4P-Pharma product offering
Product offeringCore offering
4P-Pharma is a clinical-stage biotechnology company that develops first-in-class therapies by regenerating existing drug mechanisms of action for new disease targets. It operates a startup studio model in which therapeutic candidates are sourced through open innovation with academic and AI partners, then advanced in dedicated Single Product Vehicles (SPVs) such as 4Moving Biotech and 4Living Biotech toward clinical proof of concept and eventual out-licensing to big pharma.
Product overview
4P-Pharma is a clinical-stage biotech startup studio focused on drug regeneration — developing first-in-class therapies for untreated serious diseases by repurposing existing drug mechanisms. The company operates through Single Product Vehicles (SPVs): 4Moving Biotech (osteoarthritis, 4P004), 4Living Biotech (respiratory/ophthalmology, 4P021/4P020), and Dev4All (R&D booster). The pipeline spans chronic/autoimmune diseases (4P004, 4P025), respiratory diseases (4P021), and ophthalmological conditions (4P020), leveraging AI partnerships for discovery and in-silico clinical trials for acceleration.
Differentiator
Problem solved
Functional benefit
Brands
- Dev4All: R&D booster launched by 4P-Pharma to turn innovative ideas into clinical-stage candidates
Products and services
- 4Moving Biotech Clinical-stage SPV spin-off developing first-in-class disease-modifying osteoarthritis drug (DMOAD) 4P004, a GLP-1 analog with anti-inflammatory, anti-catabolic and anabolic properties for knee osteoarthritis. Aimed at large pharma licensing and clinical collaboration partners.
- 4Living Biotech Wholly-owned SPV spin-off developing 4P021 (CXCR4 antagonist) for acute respiratory distress syndrome (ARDS) and pulmonary complications, and 4P020 for ophthalmological diseases including Stargardt disease and dry AMD. Aimed at clinical collaboration and licensing partners.
- Dev4All R&D booster entity offering biotech development services to transform innovative therapeutic ideas into clinical-stage candidates, leveraging 4P-Pharma's R&D engine and CRO expertise. Targets academic institutions, AI biotechs, and other innovators.
- 4P004 First-in-class GLP-1 analog intra-articular disease-modifying osteoarthritis drug (DMOAD) showing anti-inflammatory, anti-catabolic and anabolic properties. Developed in collaboration with Prof. Francis Berenbaum's team at St-Antoine's Hospital Paris and SATT Lutech. Currently in Phase 2a INFLAM-MOTION study across Europe and North America. Owned by SPV 4Moving Biotech.
- 4P025 Drug candidate in discovery stage for the treatment of Primary Sclerosing Cholangitis (PSC), a rare liver condition characterized by inflammation and scarring of bile ducts. Discovered in partnership with Delta4's AI platform.
- 4P020 First-in-class beta-3 adrenergic receptor agonist for Stargardt disease and dry age-related macular degeneration (dry AMD). Developed in collaboration with Institut de la Vision and SATT Lutech. Owned by SPV 4Living Biotech.
- 4P021 CXCR4 antagonist for curative treatment of acute respiratory distress syndrome (ARDS) and pulmonary complications. Developed with Prof. Patrick Berger's team at CHU de Bordeaux, INSERM, SATT Aquitaine, and Institut Pasteur de Lille. Owned by SPV 4Living Biotech.
Quantifiable outcome
- ≥ 500 candidates screened, ≥ 30 preclinical proof of concept achieved in 10 years of operations
- +2 more outcomes
Companies that use 4P-Pharma
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
4P-Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
4P-Pharma partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- Delta4corePartnership with Delta4, an AI tech company based in Vienna, Austria, to discover and develop a drug candidate for the treatment of Primary Sclerosing Cholangitis (PSC). Delta4 provides AI platform technology for drug discovery.
- OncocrosscoreCollaboration with Oncocross, a Korea-based AI tech company, to develop an AI platform-based treatment for systemic sclerosis.
- Institut de la VisioncorePartnership with Institut de la Vision for development of 4P020 (beta-3 adrenergic receptor agonist) for Stargardt disease and dry AMD.
- SATT LutechcorePartnership with SATT Lutech for technology transfer and development of therapeutic candidates including 4P020 and 4P004.
- Pasteur LillecoreStrategic partnership with Institut Pasteur de Lille for research collaboration and hosting of company headquarters.
- Academic Institutions WorldwidecoreOpen innovation partnerships with worldwide leading academic institutions to source innovative therapeutic assets.
Scale indicators6 records
Recent moves2 records
4P-Pharma competitors and assessment
Company assessmentDirect peers
- Genfit: French clinical-stage biotech developing therapies for liver diseases including Primary Sclerosing Cholangitis (PSC). Both 4P-Pharma's 4P025 program and Genfit's pipeline target PSC and rare liver conditions, making it a direct comparable for indication overlap and clinical-stage biotech dynamics.
- Biosplice (formerly Samumed): Clinical-stage biotech developing first-in-class disease-modifying osteoarthritis drugs (DMOADs), most notably lorecivivint (CLK/DYRK1 inhibitor). Direct comparator to 4P004 given shared focus on disease modification rather than symptomatic relief in knee OA.
- Intercept Pharmaceuticals: Developed obeticholic acid for primary sclerosing cholangitis and NASH, making it the most prominent historical PSC drug developer. Highly comparable to 4P025's PSC program in target indication and clinical development approach.
- CymaBay Therapeutics: Clinical-stage biotech focused on liver and inflammatory diseases, including therapies for PSC and primary biliary cholangitis (PBC). Comparable to 4P-Pharma's 4Living Biotech SPV in rare disease/liver focus and clinical-stage profile.
Broad incumbents
- Galapagos NV: Belgian-Dutch clinical-stage biotech with historical programs in osteoarthritis and immunology, including JAK inhibitors and other inflammation targets. Broader portfolio than 4P-Pharma but historically a direct competitor in OA drug development.
- Ipsen: Mid-size French pharmaceutical company with significant rare disease and specialty care franchises. Relevant as a French incumbent peer and potential strategic acquirer of 4P-Pharma's SPV assets in rare/specialty indications.
Emerging players
- Pharvaris: Clinical-stage biotech developing a single-asset (bradykinin B2 receptor antagonist) for hereditary angioedema with focused, asset-centric structure similar to 4P-Pharma's SPV model. Comparable as a focused clinical-stage company leveraging deep mechanism-of-action expertise.
- Nordic Bioscience: Danish biotech developing biomarker-driven diagnostics and DMOAD candidates for osteoarthritis and musculoskeletal diseases. Direct adjacency to 4P004's disease area and similar clinical-stage focus on novel OA mechanisms.
Others
- Novadiscovery: French healthtech applying in-silico clinical trial simulation and AI-driven trial design — closely aligned with 4P-Pharma's stated use of in-silico clinical trial technology and partnerships (QuantHealth, Delta4).
- Iktos: French AI company specializing in generative chemistry and small-molecule drug design. Comparable ecosystem player in the AI-for-drug-discovery space that 4P-Pharma leverages via Delta4, Oncocross, and QuantHealth partnerships.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
4P-Pharma social profiles
Digital presence4P-Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
4P-Pharma leadership team
Management profileNumber of profiles
Profiles14 records
4P-Pharma subsidiaries and ownership
Company hierarchySubsidiaries3 records
4P-Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
4P-Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 4P-Pharma
What does 4P-Pharma do?
4P-Pharma is a clinical-stage biotechnology company that develops first-in-class therapies by regenerating existing drug mechanisms of action for new disease targets. It operates a startup studio model in which therapeutic candidates are sourced through open innovation with academic and AI partners, then advanced in dedicated Single Product Vehicles (SPVs) such as 4Moving Biotech and 4Living Biotech toward clinical proof of concept and eventual out-licensing to big pharma.
Is 4P-Pharma a public or private company?
4P-Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was 4P-Pharma founded?
4P-Pharma was founded in 2014. It employs 11 to 50 people.
Where is 4P-Pharma based?
4P-Pharma is headquartered in Lille, France, in the Europe region.
How does 4P-Pharma make money?
Two revenue lines are on record. Therapeutic Development and Licensing is the primary driver. The others are SPV Equity Value.
Who are 4P-Pharma's main competitors?
Direct peers on record are Genfit, Biosplice (formerly Samumed), Intercept Pharmaceuticals and CymaBay Therapeutics. Broad incumbents are Galapagos NV and Ipsen. Emerging players are Pharvaris and Nordic Bioscience. Others are Novadiscovery and Iktos.
Does 4P-Pharma have an API?
No public API is recorded for 4P-Pharma.
What industry is 4P-Pharma in?
4P-Pharma's product category is Clinical-stage biotechnology / Pharmaceutical drug development. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.